Your browser doesn't support javascript.
loading
Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence.
Frey, Nicolas; Bordogna, Walter; Balas, Bogdana; Ruf, Thorsten; Archer, Venice; Guerini, Elena.
Affiliation
  • Frey N; Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Bordogna W; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Balas B; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Ruf T; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Archer V; Roche Products Ltd, Welwyn Garden City, UK.
  • Guerini E; Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Clin Pharmacol Ther ; 110(5): 1162-1163, 2021 11.
Article in En | MEDLINE | ID: mdl-34365647
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2021 Type: Article Affiliation country: Switzerland
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2021 Type: Article Affiliation country: Switzerland